Drug-Resistant Epilepsy (DRE) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Drug-Resistant Epilepsy (DRE) is associated with neuroinflammatory, autoimmune, and neurodegenerative processes. Immune, pathophysiological, biochemical, and psychological effects are all caused by neuroinflammation. Whether localized or systemic, uncontrolled inflammatory processes result in abnormal neural connections and hyperexcitable neural networks. Anti-epileptic drugs given as monotherapies or in combination fail to achieve sustained seizure freedom because inflammatory mediators affect the endothelium of cerebral vessels, destroy endothelial cell contacts, and induce abnormal angiogenesis, affecting the blood-brain barrier permeability. In 30% to 40% of patients, drug resistance develops, resulting in premature death and brain damage. Drug-resistant epilepsy (DRE) can affect patients of any age recently diagnosed with epilepsy. Patients with DRE have a lower quality of life (QOL), greater medical, social, and financial burden, and a higher mortality rate.

Epilepsy affects approximately 1.0% of the world’s population. The prevalence and frequency of epilepsy are slightly higher in men than women. The general prognosis of epilepsy is favorable for the majority of patients, and 55–68% of them tend to achieve long-term remission.

 

The competitive landscape of Drug-Resistant Epilepsy (DRE) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Drug-Resistant Epilepsy (DRE) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Drug-Resistant Epilepsy (DRE) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Drug-Resistant Epilepsy (DRE) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          ABI-009            Aadi, LLC          Phase 1

2          PLT101 PhytoTech Therapeutics, Ltd.    Phase 2

3          Vatiquinone       PTC Therapeutics         Phase 3

4          CT-010 Cerebral Therapeutics LLC        Phase 2

5          Aspirin+AED     Shijiazhuang Yiling Pharmaceutical Co. Ltd            Phase 2

6          Vanquix Auto-Injector    Pfizer    Phase 3

7          Retigabine        GlaxoSmithKline            Phase 3

8          Cannabidiol       Prati Donaduzzi & Cia Ltda        Phase 3

9          Brivaracetam    UCB Pharma    Phase 2